Tesch, Hans

Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients

Rack, B., Schindlbeck, C., Jückstock, J., Andergassen, U., Hepp, P., Zwingers, T., Friedl, T. W. P., Lorenz, R., Tesch, H., Fasching, P. A., et al. (2014) · JNCI: Journal of the National Cancer Institute

Breast Cancer Treatment StudiesCancer Cells and Metastasis

Cited by 615

Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer—results from the prospective German TMK cohort study

Fietz, T., Tesch, H., Rauh, J., Boller, E., Kruggel, L., Jänicke, M., & Marschner, N. (2017) · The Breast

Breast Cancer Treatment StudiesAdvanced Breast Cancer Therapies

Cited by 65

Subcutaneous Trastuzumab for HER2-positive Breast Cancer – Evidence and Practical Experience in 7 German Centers

Jackisch, C., Müller, V., Dall, P., Neumeister, R., Park-Simon, T.-W., Ruf-Dördelmann, A., Seiler, S., Tesch, H., & Ataseven, B. (2015) · Geburtshilfe und Frauenheilkunde

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 42

CD3×CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphoma

Manzke, O., Titzer, S., Tesch, H., Diehl, V., & Bohlen, H. (1997) · Cancer Immunology, Immunotherapy

Lymphoma Diagnosis and TreatmentMonoclonal and Polyclonal Antibodies Research

Cited by 20

ELN Treatment Milestones in Chronic Myeloid Leukemia Are Prognostic for Achieving Deep Molecular Response and Treatment-Free Remission in Routine Care: Results of the German CML Registry

Kohlbrenner, K., Galuschek, N., Fabarius, A., Reiser, M., Fenchel, K., Esseling, E., Göhler, T., Kühn, R.-B., Depenbusch, R., Talah Azeh, I., et al. (2023) · Blood

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 1